Tammy Lee
Psychiatric/Mental Health · Mobile, ALNPI 1184125445
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 493 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 493 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Vanda Pharmaceuticals Inc.$1K
- Axsome Therapeutics, Inc.$856
- Alkermes, Inc.$777
- plus $4K from 13 others
What the payments were for
- Food & beverage$11,503100%
- Education$570%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 112 | $2,251 |
| Johnson & Johnson | 85 | $1,637 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $1,329 |
| Vanda Pharmaceuticals Inc. | 39 | $1,094 |
| Axsome Therapeutics, Inc. | 27 | $856 |
| Alkermes, Inc. | 25 | $777 |
| Teva Pharmaceuticals USA, Inc. | 36 | $741 |
| Neurocrine Biosciences, Inc. | 24 | $629 |
| Otsuka America Pharmaceutical, Inc. | 18 | $534 |
| Supernus Pharmaceuticals, Inc. | 5 | $483 |
| Lundbeck LLC | 27 | $452 |
| Indivior Inc. | 15 | $270 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $198 |
| Sunovion Pharmaceuticals Inc. | 10 | $102 |
| E.r. Squibb & Sons, L.L.C. | 3 | $74 |
| Corium, LLC | 3 | $67 |
| Tris Pharma Inc | 2 | $32 |
| TG Therapeutics, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,560 in reported general payments places this provider in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 80 | $641,617 |
| Invega SustennaPaliperidone Palmitate | 205 | $582,956 |
| HetliozTasimelteon | 20 | $447,609 |
| Abilify MaintenaAripiprazole | 149 | $397,470 |
| Tasimelteon | 15 | $307,548 |
| VraylarCariprazine Hcl | 189 | $277,021 |
| AustedoDeutetrabenazine | 13 | $191,318 |
| CaplytaLumateperone Tosylate | 93 | $154,348 |
| FanaptIloperidone | 14 | $44,137 |
| TrintellixVortioxetine Hydrobromide | 44 | $26,622 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $23,384 |
| Haloperidol Decanoate | 186 | $9,506 |
| Lurasidone Hcl | 64 | $8,756 |
| Aripiprazole | 196 | $6,783 |
| Haloperidol | 174 | $5,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $629 | $641,61780 claims |
| Johnson & JohnsonInvega Sustenna | $1,637 | $582,956205 claims |
| Vanda Pharmaceuticals Inc.Hetlioz, Fanapt | $1,094 | $491,74634 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $534 | $397,470149 claims |
| AbbVieVraylar | $2,251 | $277,021189 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $741 | $191,95336 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,329 | $154,34893 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $198 | $26,62244 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $16 | $23,38423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Mobile
- John HayesMobile$30K
- Mary LeeMobile$11K
- Robert WillettMobile$10K
- Dolores BrayMobile$9K
- Beverly AlesMobile$7K
- Kina HooksMobile$7K
- Wanda WhiddonMobile$6K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.